GLP-1 drugs and early rectal effects in severe obesity
Part of Digestive system, Heart & circulation, Hormones & metabolism clinical trials.
This trial looks at how a class of diabetes/weight-loss drugs called GLP-1 receptor agonists affect the rectal area in people with severe obesity. It may help understand early side effects or benefits for your bottom health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have severe obesity (BMI 40 or higher, or BMI 35 with related health problems).
- You have just started taking a GLP-1 drug (like semaglutide, liraglutide, etc.).
- You can attend a check-up visit 3 months after starting the drug.
- You have no current or past rectal/anal cancer, inflammatory bowel disease, or recent anal surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a GLP-1 receptor agonist (a diabetes/weight-loss medication) to standard rectal cancer treatment improves outcomes for patients with rectal cancer who are overweight or obese. It is for those with mismatch repair proficient (pMMR) rectal cancer that hasn't spread and requires a specific MRI finding.
This trial tests whether adding a GLP-1 receptor agonist (a medication that helps control blood sugar and appetite) after weight loss surgery improves outcomes for people with severe obesity and related health problems like type 2 diabetes.
This study tests a drug that helps with weight loss and blood sugar (called a GLP-1 receptor agonist) combined with a special diet to see if it can improve symptoms in people with mild Crohn's disease. You may join if you have Crohn's, a BMI of 27 or higher, and are already on a stable dose of a TNF blocker.
This study tests whether a newer class of weight-loss medicines (GLP-1 and GIP/GLP-1 analogues) can help people with excess body weight eat healthier and improve their metabolism and behavior. It may be a good option if you are an adult with overweight or obesity and haven't used these medicines recently.
This study looks at whether stopping GLP-1 receptor agonists (a type of diabetes or weight-loss medication) before a colonoscopy can help improve the procedure. It compares how well the bowel is cleaned in people who stop these drugs for a certain time versus those who continue them.
This trial tests an experimental medication that may help with weight loss. It aims to see how safe the drug is and how the body responds, possibly leading to a new treatment option for obesity.
Hear when a new Anorectal Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.